Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

Elias Jabbour, Guillermo Garcia-Manero, Nicolas Batty, Jenny Shan, Susan O'Brien, Jorge Cortes, Farhad Ravandi, Jean Pierre Issa, Hagop Kantarjian

Research output: Contribution to journalArticle

145 Scopus citations

Abstract

BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.

Original languageEnglish (US)
Pages (from-to)3830-3834
Number of pages5
JournalCancer
Volume116
Issue number16
DOIs
StatePublished - Aug 15 2010
Externally publishedYes

    Fingerprint

Keywords

  • Decitabine
  • Failure
  • Myelodysplastic syndrome
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jabbour, E., Garcia-Manero, G., Batty, N., Shan, J., O'Brien, S., Cortes, J., Ravandi, F., Issa, J. P., & Kantarjian, H. (2010). Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 116(16), 3830-3834. https://doi.org/10.1002/cncr.25247